文献速递传染病防控与疫情报告

基于Subolesin的DNA与蛋白联合免疫诱导的抗成年长角血蜱交叉保护

Cross protection induced by combined Subolesin-based DNA and protein immunizations against adult Haemaphysalis longicornis.
PubMed 文献 · Vaccine · 2019-11-04

研究评估Subolesin与核糖体酸性蛋白P0肽联合疫苗接种对成年长角血蜱的交叉保护能力。先用表达subolesin的DNA疫苗初免,再用rRhSub或rRhSub/P0嵌合多肽加强,可导致长角血蜱成虫显著死亡、减少吸血和繁殖。补充rRhSub和rRhSub/P0组的疫苗效力分别为79.3%和86.6%。

要点

  • DNA初免加rRhSub或rRhSub/P0蛋白加强可诱导对长角血蜱成虫的交叉保护。
  • 补充rRhSub组疫苗效力为79.3%,补充rRhSub/P0组为86.6%。
  • 接种导致长角血蜱成虫显著死亡、吸血减少和繁殖减少。

核心结论

  • 保守抗原subolesin以DNA疫苗形式配制并用嵌合多肽增强,可作为抗蜱疫苗应用,尤其用于控制涉及多种蜱种的侵染。

研究设计与样本

  • 研究评估Subolesin与核糖体酸性蛋白0(P0)肽联合疫苗接种对成年长角血蜱的能力。

主要发现

  • 用表达subolesin的DNA疫苗初免、随后用单抗原rRhSub或嵌合多肽rRhSub/P0加强,可提供交叉保护。
  • 该处理导致长角血蜱成虫显著死亡、吸血减少和繁殖减少。
  • 补充rRhSub组疫苗效力为79.3%,补充rRhSub/P0组为86.6%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccination against ticks is an environmentally friendly alternative control method compared to chemical acaricide applications. Subolesin is a conserved protein in ticks, which can provide protection against some tick species. In this study, we evaluated the capacity of cocktail vaccination with Subolesin and ribosomal acidic protein 0 (P0) peptide against adults of Haemaphysalis longicornis. Priming with DNA vaccine expressing subolesin, followed by boosters of a single antigen (rRhSub) or a chimeric polypeptide (rRhSub/P0), provided cross protection. This treatment resulted in significant mortality, reduced blood ingestion and reduced reproduction in H. longicornis adults. Vaccination efficacies of 79.3% and 86.6% are reported in groups supplemented with rRhSub and rRhSub/P0, respectively. Conserved antigens, such as subolesin, formulated as DNA vaccine and enhanced with chimeric polypeptides, could be used as an anti-tick vaccine application, especially for control of infestation involving several tick species.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hassan IA, Wang Y, Zhou Y, et al. Cross protection induced by combined Subolesin-based DNA and protein immunizations against adult Haemaphysalis longicornis. Vaccine. 2019. PMID: 31699505. doi:10.1016/j.vaccine.2019.10.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。